应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
FDMT 4D Molecular Therapeutics
盘前交易 03-23 04:19:54 EDT
8.61
-0.37
-4.12%
最高
9.10
最低
8.59
成交量
137.36万
今开
8.63
昨收
8.98
日振幅
5.62%
总市值
4.39亿
流通市值
3.17亿
总股本
5,101万
成交额
1,196万
换手率
3.73%
流通股本
3,678万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
4D分子治疗发布2025财年业绩：基因疗法管线迎关键里程碑，现金储备可支撑至2027年
美股速递 · 03-19
4D分子治疗发布2025财年业绩：基因疗法管线迎关键里程碑，现金储备可支撑至2027年
4D Molecular Therapeutics, Inc.盘中异动 股价大涨5.27%
市场透视 · 01-27
4D Molecular Therapeutics, Inc.盘中异动 股价大涨5.27%
4Dmt公布4D-710 Aerow一期临床试验在囊性纤维化肺病中的积极中期临床数据
美股速递 · 2025-12-17
4Dmt公布4D-710 Aerow一期临床试验在囊性纤维化肺病中的积极中期临床数据
4DMT公布长期1/2期数据 表明4D-150在湿性AMD治疗中的持久多年疗效
投资观察 · 2025-11-20
4DMT公布长期1/2期数据 表明4D-150在湿性AMD治疗中的持久多年疗效
4D Molecular Therapeutics, Inc.盘中异动 急速下挫5.21%报10.38美元
市场透视 · 2025-11-19
4D Molecular Therapeutics, Inc.盘中异动 急速下挫5.21%报10.38美元
异动解读 | 4D Molecular Therapeutics盘中大涨5.19%，任命华尔街资深人士为新CFO
异动解读 · 2025-11-17
异动解读 | 4D Molecular Therapeutics盘中大涨5.19%，任命华尔街资深人士为新CFO
新闻稿：4DMT任命Kristian Humer为首席财务官
投资观察 · 2025-11-17
新闻稿：4DMT任命Kristian Humer为首席财务官
异动解读 | 4D分子治疗股价盘中大涨5.21%，分析师上调目标价
异动解读 · 2025-11-11
异动解读 | 4D分子治疗股价盘中大涨5.21%，分析师上调目标价
4D分子疗法发布2025年第三季度财务结果、运营亮点及预期里程碑
美股速递 · 2025-11-10
4D分子疗法发布2025年第三季度财务结果、运营亮点及预期里程碑
4D Molecular Therapeutics, Inc.盘中异动 早盘股价大涨8.09%报11.36美元
市场透视 · 2025-11-06
4D Molecular Therapeutics, Inc.盘中异动 早盘股价大涨8.09%报11.36美元
4Dmt发布湿性年龄相关性黄斑变性Prism 1/2期临床试验的积极长期数据，支持4D-150作为具有持续和耐久效果的基础治疗潜力
美股速递 · 2025-11-06
4Dmt发布湿性年龄相关性黄斑变性Prism 1/2期临床试验的积极长期数据，支持4D-150作为具有持续和耐久效果的基础治疗潜力
4D Molecular Therapeutics, Inc.盘中异动 早盘股价大跌5.04%
市场透视 · 2025-11-03
4D Molecular Therapeutics, Inc.盘中异动 早盘股价大跌5.04%
4D Molecular Therapeutics与大冢制药达成协议，授予其在亚太地区对 4D-150基因疗法的权利4D Molecular Therapeutics Partners with Otsuka Pharmaceutical for Asia-Pacific Rights to 4D-150 Gene Therapy
动脉网 · 2025-11-03
4D Molecular Therapeutics与大冢制药达成协议，授予其在亚太地区对 4D-150基因疗法的权利4D Molecular Therapeutics Partners with Otsuka Pharmaceutical for Asia-Pacific Rights to 4D-150 Gene Therapy
4Dmt 与大冢制药签署独家许可协议，以在亚太地区开发和商业化 4D-150
美股速递 · 2025-10-31
4Dmt 与大冢制药签署独家许可协议，以在亚太地区开发和商业化 4D-150
4D Molecular Therapeutics推进4D-710进入二期临床试验，获得囊性纤维化基金会额外资金支持
美股速递 · 2025-10-13
4D Molecular Therapeutics推进4D-710进入二期临床试验，获得囊性纤维化基金会额外资金支持
4D Molecular Therapeutics任命Ashoo Gupta为首席财务官
美股速递 · 2025-10-03
4D Molecular Therapeutics任命Ashoo Gupta为首席财务官
4D Molecular Therapeutics, Inc.盘中异动 股价大跌5.04%
市场透视 · 2025-03-11
4D Molecular Therapeutics, Inc.盘中异动 股价大跌5.04%
B of A Securities：维持4D Molecular Therapeutics(FDMT.US)评级，由买入调整至买入评级, 目标价由42.00美元调整至40.00美元。
金融界 · 2025-03-11
B of A Securities：维持4D Molecular Therapeutics(FDMT.US)评级，由买入调整至买入评级, 目标价由42.00美元调整至40.00美元。
4D Molecular Therapeutics, Inc.盘中异动 急速下挫5.31%
市场透视 · 2025-03-04
4D Molecular Therapeutics, Inc.盘中异动 急速下挫5.31%
4D Molecular Therapeutics, Inc.盘中异动 股价大涨5.41%报4.78美元
市场透视 · 2025-03-03
4D Molecular Therapeutics, Inc.盘中异动 股价大涨5.41%报4.78美元
加载更多
公司概况
公司名称：
4D Molecular Therapeutics
所属市场：
NASDAQ
上市日期：
--
主营业务：
4D Molecular Therapeutics, Inc.于2015年3月11日根据特拉华州法律成立。该公司是一家领先的临床阶段生物制药公司，专注于通过针对特定疾病治疗进行优化的专有定制载体释放基因药物的全部潜力。
发行价格：
--
{"stockData":{"symbol":"FDMT","market":"US","secType":"STK","nameCN":"4D Molecular Therapeutics","latestPrice":8.61,"timestamp":1774036800000,"preClose":8.98,"halted":0,"volume":1373562,"delay":0,"changeRate":-0.041202672605790754,"floatShares":36783600,"shares":51007900,"eps":-2.418583,"marketStatus":"盘前交易","change":-0.37,"latestTime":"03-23 04:19:54 EDT","open":8.63,"high":9.095,"low":8.59,"amount":11957002.807572,"amplitude":0.056236,"askPrice":12.15,"askSize":100,"bidPrice":6.86,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-2.418583,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1774272600000},"marketStatusCode":1,"adr":0,"listingDate":1607662800000,"exchange":"NASDAQ","adjPreClose":8.61,"postHourTrading":{"tag":"盘后","latestPrice":8.61,"preClose":8.61,"latestTime":"18:03 EDT","volume":152884,"amount":1316326.804,"timestamp":1774044222304,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":2.774098510839772,"impliedVol":0.9209,"impliedVolPercentile":0.452},"requestUrl":"/m/hq/s/FDMT","defaultTab":"news","newsList":[{"id":"1124470569","title":"4D分子治疗发布2025财年业绩：基因疗法管线迎关键里程碑，现金储备可支撑至2027年","url":"https://stock-news.laohu8.com/highlight/detail?id=1124470569","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124470569?lang=zh_cn&edition=full","pubTime":"2026-03-19 04:09","pubTimestamp":1773864570,"startTime":"0","endTime":"0","summary":"4D分子治疗公布2025财年全年财务业绩，显示公司研发投入持续加大，现金及现金等价物余额达3.2亿美元。根据管理层测算，当前资金规模足以支持公司运营至2027年下半年，为多项中期临床项目的推进提供了财务保障。4D分子治疗专注于利用其专有的载体进化平台开发靶向基因疗法，目前管线覆盖眼科、肺病及罕见病领域。这些里程碑事件可能成为股价表现的重要驱动因素。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FDMT","BK4139"],"gpt_icon":0},{"id":"2606758798","title":"4D Molecular Therapeutics, Inc.盘中异动 股价大涨5.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2606758798","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606758798?lang=zh_cn&edition=full","pubTime":"2026-01-27 23:52","pubTimestamp":1769529169,"startTime":"0","endTime":"0","summary":"北京时间2026年01月27日23时52分，4D Molecular Therapeutics, Inc.股票出现波动，股价快速拉升5.27%。4D Molecular Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为1.60%。其相关个股中，Biomx Inc.、Briacell Therapeutics Corp C/Wts 、Lisata Therapeutics, Inc.涨幅较大，Biomx Inc.、Vyome Holdings, Inc.、Genenta Science Spa较为活跃，换手率分别为1549.94%、737.59%、227.51%，振幅较大的相关个股有Biomx Inc.、Vyome Holdings, Inc.、Novabay Pharmaceuticals, Inc.，振幅分别为53.90%、39.87%、36.19%。4D Molecular Therapeutics, Inc.公司简介：4D Molecular Therapeutics Inc 是一家临床阶段基因治疗公司，从事使用靶向和进化的AAV载体开发候选产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260127235249a6b3b642&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260127235249a6b3b642&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4539","FDMT","BK4007","BK4139","LENZ"],"gpt_icon":0},{"id":"1194674477","title":"4Dmt公布4D-710 Aerow一期临床试验在囊性纤维化肺病中的积极中期临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1194674477","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1194674477?lang=zh_cn&edition=full","pubTime":"2025-12-17 20:04","pubTimestamp":1765973090,"startTime":"0","endTime":"0","summary":"4Dmt公布4D-710 Aerow一期临床试验在囊性纤维化肺病中的积极中期临床数据","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FDMT"],"gpt_icon":0},{"id":"1117823889","title":"4DMT公布长期1/2期数据 表明4D-150在湿性AMD治疗中的持久多年疗效","url":"https://stock-news.laohu8.com/highlight/detail?id=1117823889","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117823889?lang=zh_cn&edition=full","pubTime":"2025-11-20 00:57","pubTimestamp":1763571442,"startTime":"0","endTime":"0","summary":"11月6日 - 4D Molecular Therapeutics Inc宣布，来自1/2期PRISM临床试验的积极长期数据支持4D-150作为核心治疗的潜力，其在多年的治疗中展现出一致和持久的疗效。4D Molecular Therapeutics Inc表示，4D-150的耐受性良好，未出现新的安全问题。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FDMT"],"gpt_icon":0},{"id":"2584999524","title":"4D Molecular Therapeutics, Inc.盘中异动 急速下挫5.21%报10.38美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2584999524","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584999524?lang=zh_cn&edition=full","pubTime":"2025-11-19 01:46","pubTimestamp":1763487970,"startTime":"0","endTime":"0","summary":"北京时间2025年11月19日01时46分，4D Molecular Therapeutics, Inc.股票出现异动，股价大幅下挫5.21%。4D Molecular Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.38%。其相关个股中，Olema Pharmaceuticals, Inc.、Aspire Biopharma Holdings, Inc.、Seastar Medical Holding Corp C/Wts 28/10/2027 涨幅较大，Can Fite Biopharma Ltd、Clearmind Medicine Inc.、Aspire Biopharma Holdings, Inc.较为活跃，换手率分别为1960.79%、1130.01%、409.89%，振幅较大的相关个股有Olema Pharmaceuticals, Inc.、Clearmind Medicine Inc.、Can Fite Biopharma Ltd，振幅分别为106.34%、60.49%、59.39%。4D Molecular Therapeutics, Inc.公司简介：4D Molecular Therapeutics Inc 是一家临床阶段基因治疗公司，从事使用靶向和进化的AAV载体开发候选产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251119014611a4aad157&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251119014611a4aad157&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4539","BK4139","LENZ","BK4007","FDMT"],"gpt_icon":0},{"id":"1151414580","title":"异动解读 | 4D Molecular Therapeutics盘中大涨5.19%，任命华尔街资深人士为新CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=1151414580","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151414580?lang=zh_cn&edition=full","pubTime":"2025-11-17 23:50","pubTimestamp":1763394659,"startTime":"0","endTime":"0","summary":"4D Molecular Therapeutics今日盘中大涨5.19%，引发市场关注。该公司股价上涨可能与其最新人事任命有关。根据公司发布的新闻稿，4D Molecular Therapeutics宣布任命Kristian Humer为新任首席财务官。分析人士认为，Humer的加入对4D Molecular Therapeutics来说是一个积极信号。Humer的华尔街背景和生物技术行业经验可能会帮助公司优化财务战略，提升资本市场表现，并可能为未来的融资和商业化准备奠定基础。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["FDMT"],"gpt_icon":0},{"id":"1165878861","title":"新闻稿：4DMT任命Kristian Humer为首席财务官","url":"https://stock-news.laohu8.com/highlight/detail?id=1165878861","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1165878861?lang=zh_cn&edition=full","pubTime":"2025-11-17 19:01","pubTimestamp":1763377280,"startTime":"0","endTime":"0","summary":"加利福尼亚州埃默里维尔，2025年11月17日-- 4D Molecular Therapeutics，一家领先的晚期生物技术公司，致力于开发持久且针对疾病的疗法，旨在转变治疗模式并为患者提供前所未有的益处，今天宣布任命Kristian Humer为首席财务官。Humer先生将负责公司的财务战略和运营，包括财务规划、资本配置、企业发展及支持战略举措的责任。Kristian持有杜克大学富克商学院的MBA学位，以及雷丁大学的会计与经济学荣誉学士学位。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4604","BK4555","FDMT","03160","BK4139","TM","BK4585","BK4588","BK4099"],"gpt_icon":0},{"id":"1128526510","title":"异动解读 | 4D分子治疗股价盘中大涨5.21%，分析师上调目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1128526510","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128526510?lang=zh_cn&edition=full","pubTime":"2025-11-11 23:26","pubTimestamp":1762874796,"startTime":"0","endTime":"0","summary":"4D分子治疗（FDMT）股价今日盘中大涨5.21%，引发投资者关注。这一显著涨幅似乎与多家分析机构上调公司目标股价有关。\n\n据悉，Chardan Capital Markets将4D分子治疗的目标价从25美元上调至26美元。同时，加拿大皇家银行更是大幅提高了其目标价，从26美元上调至32美元，显示出分析师对公司前景的乐观态度。\n\n分析人士认为，目标价的上调反映了市场对4D分子治疗公司未来发展前景的信心增强。这可能源于公司在基因疗法研发领域取得的进展，或者最近发布的积极财务业绩。然而，具体原因还有待公司或分析师进一步披露更多细节。投资者对这一利好消息反应积极，推动了股价的大幅上涨。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["FDMT"],"gpt_icon":0},{"id":"1102064836","title":"4D分子疗法发布2025年第三季度财务结果、运营亮点及预期里程碑","url":"https://stock-news.laohu8.com/highlight/detail?id=1102064836","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1102064836?lang=zh_cn&edition=full","pubTime":"2025-11-10 21:03","pubTimestamp":1762779794,"startTime":"0","endTime":"0","summary":"4D分子疗法发布2025年第三季度财务结果、运营亮点及预期里程碑","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FDMT"],"gpt_icon":0},{"id":"2581008335","title":"4D Molecular Therapeutics, Inc.盘中异动 早盘股价大涨8.09%报11.36美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2581008335","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581008335?lang=zh_cn&edition=full","pubTime":"2025-11-06 22:33","pubTimestamp":1762439621,"startTime":"0","endTime":"0","summary":"北京时间2025年11月06日22时33分，4D Molecular Therapeutics, Inc.股票出现异动，股价急速拉升8.09%。4D Molecular Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.02%。4D Molecular Therapeutics, Inc.公司简介：4D Molecular Therapeutics Inc 是一家临床阶段基因治疗公司，从事使用靶向和进化的AAV载体开发候选产品。消息层面，截至22时33分，《4D Molecular Therapeutics与大冢制药达成协议，授予其在亚太地区对 4D-150基因疗法的权利4D Molecular Therapeutics Partners with Otsuka Pharmaceutical for Asia-Pacific Rights to 4D-150 Gene Therapy》资讯为影响4D Molecular Therapeutics, Inc.的重要信息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251106223341a6e634be&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251106223341a6e634be&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","BK4007","BK4539","FDMT"],"gpt_icon":0},{"id":"1173035067","title":"4Dmt发布湿性年龄相关性黄斑变性Prism 1/2期临床试验的积极长期数据，支持4D-150作为具有持续和耐久效果的基础治疗潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=1173035067","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1173035067?lang=zh_cn&edition=full","pubTime":"2025-11-06 19:01","pubTimestamp":1762426915,"startTime":"0","endTime":"0","summary":"4Dmt发布了来自湿性年龄相关性黄斑变性Prism 1/2期临床试验的积极长期数据，进一步支持了4D-150作为一种基础治疗的潜力，其效果显著且持续多年。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FDMT","BK4139"],"gpt_icon":0},{"id":"2580217158","title":"4D Molecular Therapeutics, Inc.盘中异动 早盘股价大跌5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580217158","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580217158?lang=zh_cn&edition=full","pubTime":"2025-11-03 23:19","pubTimestamp":1762183189,"startTime":"0","endTime":"0","summary":"北京时间2025年11月03日23时19分，4D Molecular Therapeutics, Inc.股票出现波动，股价大幅下跌5.04%。4D Molecular Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为1.28%。4D Molecular Therapeutics, Inc.公司简介：4D Molecular Therapeutics Inc 是一家临床阶段基因治疗公司，从事使用靶向和进化的AAV载体开发候选产品。消息层面，截至23时19分，《4D Molecular Therapeutics与大冢制药达成协议，授予其在亚太地区对 4D-150基因疗法的权利4D Molecular Therapeutics Partners with Otsuka Pharmaceutical for Asia-Pacific Rights to 4D-150 Gene Therapy》资讯为影响4D Molecular Therapeutics, Inc.的重要信息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110323195094ec68b1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110323195094ec68b1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","BK4539","FDMT","BK4139","LENZ"],"gpt_icon":0},{"id":"2580171302","title":"4D Molecular Therapeutics与大冢制药达成协议，授予其在亚太地区对 4D-150基因疗法的权利4D Molecular Therapeutics Partners with Otsuka Pharmaceutical for Asia-Pacific Rights to 4D-150 Gene Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2580171302","media":"动脉网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580171302?lang=zh_cn&edition=full","pubTime":"2025-11-03 17:04","pubTimestamp":1762160640,"startTime":"0","endTime":"0","summary":"by GOAI由GOAI生成Share To分享到4D Molecular Therapeutics has entered into an exclusive license agreement with Otsuka Pharmaceutical for the development and commercialization of 4D-150 in the Asia-Pacific region. The collaboration focuses on advancing treatment options for eye diseases, particularly targeting wet age-related macular degeneration and diabetic macular edema ..4D Molecular Therapeutics与大冢制药达成了一项独家许可协议，授权其在亚太地区开发和商业化4D-150。This partnership aims to leverage Otsuka’s regional expertise alongside 4DMT’s proprietary technology platform to expand access to innovative treatments for patients suffering from these conditions..该合作伙伴关系旨在利用大冢的区域专业知识和4DMT的专有技术平台，扩大这些疾病患者获得创新治疗的机会。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110317061794ebc090&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110317061794ebc090&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4539","BK4139","LENZ","BK4007","FDMT"],"gpt_icon":0},{"id":"1185212371","title":"4Dmt 与大冢制药签署独家许可协议，以在亚太地区开发和商业化 4D-150","url":"https://stock-news.laohu8.com/highlight/detail?id=1185212371","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1185212371?lang=zh_cn&edition=full","pubTime":"2025-10-31 11:03","pubTimestamp":1761879787,"startTime":"0","endTime":"0","summary":"4Dmt 与大冢制药签署独家许可协议，以在亚太地区开发和商业化 4D-150","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FDMT"],"gpt_icon":0},{"id":"1195683476","title":"4D Molecular Therapeutics推进4D-710进入二期临床试验，获得囊性纤维化基金会额外资金支持","url":"https://stock-news.laohu8.com/highlight/detail?id=1195683476","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1195683476?lang=zh_cn&edition=full","pubTime":"2025-10-13 20:03","pubTimestamp":1760357018,"startTime":"0","endTime":"0","summary":"4D Molecular Therapeutics宣布其4D-710项目成功推进至二期临床试验阶段，同时获得了囊性纤维化基金会提供的额外资金和支持。这一进展标志着该公司在治疗囊性纤维化疾病方面取得重要里程碑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FDMT"],"gpt_icon":0},{"id":"1139757037","title":"4D Molecular Therapeutics任命Ashoo Gupta为首席财务官","url":"https://stock-news.laohu8.com/highlight/detail?id=1139757037","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139757037?lang=zh_cn&edition=full","pubTime":"2025-10-03 04:08","pubTimestamp":1759435691,"startTime":"0","endTime":"0","summary":"4D Molecular Therapeutics Inc于9月30日任命Ashoo Gupta为公司首席财务官，该消息通过SEC备案文件披露。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FDMT","BK4139"],"gpt_icon":0},{"id":"2518203767","title":"4D Molecular Therapeutics, Inc.盘中异动 股价大跌5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518203767","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518203767?lang=zh_cn&edition=full","pubTime":"2025-03-11 01:38","pubTimestamp":1741628301,"startTime":"0","endTime":"0","summary":"北京时间2025年03月11日01时38分，4D Molecular Therapeutics, Inc.股票出现异动，股价大幅下跌5.04%。4D Molecular Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.83%。其相关个股中，Aeon Biopharma, Inc.、Mineralys Therapeutics, Inc.、Checkpoint Therapeutics, Inc.涨幅较大，Aeon Biopharma, Inc.、Biodexa Pharmaceuticals Plc、Scisparc Ltd.较为活跃，换手率分别为5248.29%、3822.86%、989.14%，振幅较大的相关个股有Aeon Biopharma, Inc.、Protagenic Therapeutics Inc C/Wts 29/04/2026 、Biodexa Pharmaceuticals Plc，振幅分别为90.44%、88.14%、58.34%。4D Molecular Therapeutics, Inc.公司简介：4D Molecular Therapeutics Inc 是一家临床阶段基因治疗公司，从事使用靶向和进化的AAV载体开发候选产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311013822abf35662&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311013822abf35662&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","FDMT","BK4139"],"gpt_icon":0},{"id":"2518039742","title":"B of A Securities：维持4D Molecular Therapeutics(FDMT.US)评级，由买入调整至买入评级, 目标价由42.00美元调整至40.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2518039742","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518039742?lang=zh_cn&edition=full","pubTime":"2025-03-11 01:02","pubTimestamp":1741626170,"startTime":"0","endTime":"0","summary":"B of A Securities：维持4D Molecular Therapeutics(FDMT.US)评级，由买入调整至买入评级, 目标价由42.00美元调整至40.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/11010248641319.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LENZ","FDMT"],"gpt_icon":0},{"id":"2516677872","title":"4D Molecular Therapeutics, Inc.盘中异动 急速下挫5.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516677872","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516677872?lang=zh_cn&edition=full","pubTime":"2025-03-04 22:38","pubTimestamp":1741099111,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日22时38分，4D Molecular Therapeutics, Inc.股票出现异动，股价大幅下挫5.31%。4D Molecular Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.09%。其相关个股中，Cero Therapeutics Holdings Inc C/Wts 13/02/2029 、Protagenic Therapeutics, Inc.、Exicure, Inc.涨幅较大，Aeon Biopharma, Inc.、Windtree Therapeutics, Inc.、Protagenic Therapeutics, Inc.较为活跃，换手率分别为1098.02%、1092.28%、428.16%，振幅较大的相关个股有Celularity Inc C/Wts 16/07/2026 、Hepion Pharmaceuticals, Inc.、Windtree Therapeutics, Inc.，振幅分别为37.67%、22.25%、19.21%。4D Molecular Therapeutics, Inc.公司简介：4D Molecular Therapeutics Inc 是一家临床阶段基因治疗公司，从事使用靶向和进化的AAV载体开发候选产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304223831abe7f210&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304223831abe7f210&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","FDMT","BK4139"],"gpt_icon":0},{"id":"2516634461","title":"4D Molecular Therapeutics, Inc.盘中异动 股价大涨5.41%报4.78美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516634461","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516634461?lang=zh_cn&edition=full","pubTime":"2025-03-03 22:36","pubTimestamp":1741012585,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日22时36分，4D Molecular Therapeutics, Inc.股票出现异动，股价急速上涨5.41%。4D Molecular Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.28%。其相关个股中，Entero Therapeutics Inc.、Alto Neuroscience, Inc.、Geovax Labs, Inc.涨幅较大，Allarity Therapeutics, Inc.、Entero Therapeutics Inc.、Aeon Biopharma, Inc.较为活跃，换手率分别为48.35%、32.71%、30.88%，振幅较大的相关个股有Entero Therapeutics Inc.、Spruce Biosciences, Inc.、Pliant Therapeutics, Inc.，振幅分别为21.22%、19.25%、16.68%。4D Molecular Therapeutics, Inc.公司简介：4D Molecular Therapeutics Inc 是一家临床阶段基因治疗公司，从事使用靶向和进化的AAV载体开发候选产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303223626989a10bf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303223626989a10bf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["FDMT","LENZ","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.4dmoleculartherapeutics.com","stockEarnings":[{"period":"1week","weight":0.0336},{"period":"1month","weight":-0.0611},{"period":"3month","weight":-0.0081},{"period":"6month","weight":0.3045},{"period":"1year","weight":1.296},{"period":"ytd","weight":0.148}],"compareEarnings":[{"period":"1week","weight":-0.0207},{"period":"1month","weight":-0.055},{"period":"3month","weight":-0.047},{"period":"6month","weight":-0.0228},{"period":"1year","weight":0.1469},{"period":"ytd","weight":-0.0489}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"4D Molecular Therapeutics, Inc.于2015年3月11日根据特拉华州法律成立。该公司是一家领先的临床阶段生物制药公司，专注于通过针对特定疾病治疗进行优化的专有定制载体释放基因药物的全部潜力。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.04533},{"month":2,"riseRate":0.333333,"avgChangeRate":0.049284},{"month":3,"riseRate":0.5,"avgChangeRate":-0.03803},{"month":4,"riseRate":0.4,"avgChangeRate":-0.095608},{"month":5,"riseRate":0.6,"avgChangeRate":-0.116225},{"month":6,"riseRate":0.2,"avgChangeRate":-0.057799},{"month":7,"riseRate":0.8,"avgChangeRate":0.089973},{"month":8,"riseRate":0.4,"avgChangeRate":0.033931},{"month":9,"riseRate":0.4,"avgChangeRate":-0.036288},{"month":10,"riseRate":0.4,"avgChangeRate":-0.024776},{"month":11,"riseRate":0.6,"avgChangeRate":0.385036},{"month":12,"riseRate":0.2,"avgChangeRate":-0.036146}],"exchange":"NASDAQ","name":"4D Molecular Therapeutics","nameEN":"4D Molecular Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.37.0","shortVersion":"4.37.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"4D Molecular Therapeutics(FDMT)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供4D Molecular Therapeutics(FDMT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"4D Molecular Therapeutics,FDMT,4D Molecular Therapeutics股票,4D Molecular Therapeutics股票老虎,4D Molecular Therapeutics股票老虎国际,4D Molecular Therapeutics行情,4D Molecular Therapeutics股票行情,4D Molecular Therapeutics股价,4D Molecular Therapeutics股市,4D Molecular Therapeutics股票价格,4D Molecular Therapeutics股票交易,4D Molecular Therapeutics股票购买,4D Molecular Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"4D Molecular Therapeutics(FDMT)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供4D Molecular Therapeutics(FDMT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}